Literature DB >> 1699345

Urinary NAG excretion after anesthesia-free extracorporeal lithotripsy of renal stones: a marker of early tubular damage.

A Trinchieri1, G Zanetti, P Tombolini, A Mandressi, M Ruoppolo, M Tura, E Montanari, E Pisani.   

Abstract

Second generation lithotripters require a higher number of shocks per session as well as an increased rate of secondary treatments for complete stone disintegration compared to the original spark gap lithotripter. The clinical relevance of biological side effects caused by such treatment are less known. We evaluated urinary excretion of N-acetyl-glucosaminidase (NAG) before and after lithotripsy in 50 patients treated with a low pressure spark gap lithotripter (Dornier HM3) and in 36 patients treated with a piezoelectric lithotripter (Wolf Piezolith 2200) in an attempt to evaluate their side effects on renal tissue. The urinary excretion of NAG increased after both spark gap lithotripsy using the modified HM3 and piezoelectric lithotripsy. These changes may be associated with slight tubular damage that would occur after anesthesia-free lithotripsy in patients subjected both to a high number of shocks and to secondary treatments.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1699345     DOI: 10.1007/bf00294769

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  10 in total

1.  Renal tubular damage after renal stone treatment.

Authors:  A Trinchieri; A Mandressi; G Zanetti; M Ruoppolo; P Tombolini; E Pisani
Journal:  Urol Res       Date:  1988

2.  Extracorporeal shock wave lithotripsy and its effect on renal function.

Authors:  B R Gilbert; R A Riehle; E D Vaughan
Journal:  J Urol       Date:  1988-03       Impact factor: 7.450

3.  New generator for low pressure lithotripsy with the Dornier HM3: preliminary experience of 2 centers.

Authors:  J Graff; A Schmidt; J Pastor; D Herberhold; J Rassweiler; U Hankemeier
Journal:  J Urol       Date:  1988-05       Impact factor: 7.450

4.  Morphological changes in canine kidneys following extra-corporeal shock wave treatment.

Authors:  P Jaeger; F Redha; G Uhlschmid; D Hauri
Journal:  Urol Res       Date:  1988

5.  Side effects of extracorporeal shock-wave exposure in patients treated by extracorporeal shock-wave lithotripsy for upper urinary tract stone.

Authors:  T Kishimoto; K Yamamoto; T Sugimoto; H Yoshihara; M Maekawa
Journal:  Eur Urol       Date:  1986       Impact factor: 20.096

6.  Kidney changes after extracorporeal shock wave lithotripsy: CT evaluation.

Authors:  J I Rubin; P H Arger; H M Pollack; M P Banner; B G Coleman; M C Mintz; K N VanArsdalen
Journal:  Radiology       Date:  1987-01       Impact factor: 11.105

7.  Renal morphology and function immediately after extracorporeal shock-wave lithotripsy.

Authors:  J V Kaude; C M Williams; M R Millner; K N Scott; B Finlayson
Journal:  AJR Am J Roentgenol       Date:  1985-08       Impact factor: 3.959

8.  Renal stone disease treated with extracorporeal shock wave lithotripsy: short-term observations in 100 patients.

Authors:  J R Grantham; M R Millner; J V Kaude; B Finlayson; P T Hunter; R C Newman
Journal:  Radiology       Date:  1986-01       Impact factor: 11.105

9.  Painless piezoelectric extracorporeal lithotripsy.

Authors:  M Marberger; C Türk; I Steinkogler
Journal:  J Urol       Date:  1988-04       Impact factor: 7.450

10.  Evaluation of renal damage in extracorporeal lithotripsy by shock waves.

Authors:  F J Ruiz Marcellán; L Ibarz Servio
Journal:  Eur Urol       Date:  1986       Impact factor: 20.096

  10 in total
  2 in total

1.  The effect of extracorporeal electromagnetic shock waves on renal proximal tubular function.

Authors:  Z Kirkali; G Kirkali; Y Tahiri
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

Review 2.  Experimental basis of shockwave-induced renal trauma in the model of the canine kidney.

Authors:  J Rassweiler; K U Köhrmann; W Back; S Fröhner; M Raab; A Weber; F Kahmann; E Marlinghaus; K P Jünemann; P Alken
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.